Supplemental Table A1 Propensity score model results for the probability of diagnosis of HBV infection

Parameter	Estimate	Odds ratio	95% CI Lower	Upper	p value
Age, per year	-0.0411	0.96	0.959	0.961	<0.0001
Male sex	0.4718	1.603	1.568	1.638	<0.0001
Year of index date					
2000		1			
2001	-0.1146	0.892	0.822	0.967	0.0055
2002	-0.2589	0.772	0.714	0.835	<0.0001
2003	-0.4023	0.669	0.619	0.723	<0.0001
2004	-0.4794	0.619	0.575	0.667	<0.0001
2005	-0.5758	0.562	0.523	0.605	<0.0001
2006	-0.6641	0.515	0.479	0.553	<0.0001
2007	-0.7626	0.466	0.434	0.501	<0.0001
2008	-0.8804	0.415	0.386	0.446	<0.0001
2009	-0.9874	0.373	0.347	0.401	<0.0001
2010	-1.0996	0.333	0.31	0.358	<0.0001
2011	-1.2988	0.273	0.254	0.293	<0.0001
2012	-1.3871	0.25	0.232	0.269	<0.0001
Month of index date					
January		1			
February	-0.0141	0.986	0.933	1.042	0.6135
March	-0.0354	0.965	0.916	1.016	0.18
April	-0.0224	0.978	0.929	1.03	0.3935
May	-0.044	0.957	0.909	1.007	0.0913
June	-0.0566	0.945	0.897	0.995	0.0315
July	-0.0694	0.933	0.887	0.982	0.0074
August	-0.0812	0.922	0.876	0.97	0.0017
September	-0.1023	0.903	0.858	0.95	<0.0001
October	-0.0938	0.91	0.865	0.958	0.0003
November	-0.116	0.891	0.846	0.937	<0.0001
December	-0.1214	0.886	0.842	0.932	<0.0001
Monthly income, NT$					
Dependent		1			
<19,100	-0.1658	0.847	0.819	0.876	<0.0001
19,100–41,999	0.1102	1.116	1.087	1.147	<0.0001
≥42,000	0.2833	1.328	1.279	1.377	<0.0001

Urbanisation level					
1 (urban)		1			
2	-0.0904	0.914	0.894	0.934	<0.0001
3	-0.1119	0.894	0.847	0.944	<0.0001
4 (rural)	-0.0171	0.983	0.877	1.103	0.7708
Outpatient visits to metabolism and endocrinology professionals in the past year					
0					
1–5	0.158	1.171	1.13	1.214	<0.0001
6–10	-0.1084	0.897	0.84	0.959	0.0014
>10	-0.0625	0.939	0.845	1.044	0.2474
Charlson Comorbidity Index score[a]	0.1398	1.15	1.143	1.157	<0.0001
Adapted Diabetes Complications Severity Index score[b]	-0.073	0.93	0.917	0.942	<0.0001
Duration of diabetes, months	0.0028	1.003	1.003	1.003	<0.0001
Anti-diabetic drugs					
Acarbose	0.0507	1.052	0.977	1.133	0.18
Sulfonylurea	0.1154	1.122	1.084	1.162	<0.0001
Insulin	0.2091	1.233	1.145	1.327	<0.0001
Metformin	0.151	1.163	1.122	1.206	<0.0001
Thiazolidinedione	-0.3096	0.734	0.677	0.795	<0.0001
Dipeptidyl peptidase-4 inhibitor	0.0812	1.085	0.976	1.205	0.1308
Anti-hypertensive drugs					
Alpha blocker	-0.081	0.922	0.833	1.02	0.1164
Beta blocker	0.032	1.032	0.991	1.076	0.1247
Calcium channel blocker	-0.0569	0.945	0.908	0.982	0.0044
Diuretic	0.3296	1.39	1.33	1.454	<0.0001
ACE inhibitor/ARB	-0.0856	0.918	0.882	0.955	<0.0001
Other concomitant medications					
Antiplatelet	-0.185	0.831	0.791	0.873	<0.0001
Steroid	-0.1578	0.854	0.814	0.896	<0.0001
Antidepressant	0.0542	1.056	0.991	1.125	0.0936
Statin	-0.4718	0.624	0.592	0.658	<0.0001
PPI	1.1059	3.022	2.864	3.189	<0.0001
NSAID	0.0767	1.08	1.053	1.108	<0.0001
Comorbidities					
Hypertension	-0.1764	0.838	0.818	0.859	<0.0001
Coronary artery disease	0.0571	1.059	1.028	1.09	0.0002
Heart failure	-0.3525	0.703	0.666	0.741	<0.0001

Peptic ulcer disease	0.1731	1.189	1.162	1.217	<0.0001
Chronic kidney disease	0.0234	1.024	0.993	1.055	0.1335
Atrial fibrillation	-0.1366	0.872	0.792	0.961	0.0057
Dyslipidaemia	0.103	1.108	1.084	1.133	<0.0001
Valvular heart disease	0.0353	1.036	0.992	1.082	0.1102
Cancer	0.1052	1.111	1.07	1.153	<0.0001
Autoimmune disease	0.0809	1.084	1.028	1.144	0.0031
Physical limitation	0.0747	1.078	1.021	1.137	0.0063

[a] Used to determine overall systemic health; each increase reflects a stepwise increase in cumulative mortality.

[b] A 13-point scale with 7 complication categories: retinopathy, nephropathy, neuropathy, cerebrovascular, cardiovascular, peripheral vascular disease, and metabolic.
Each complication is given a numeric score ranging from 0 to 2 (0 = no abnormality, 1 = some abnormality, 2 = severe abnormality).

Abbreviations: CI, confidence interval; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; PPI, proton pump inhibitor; NSAID, non-steroidal anti-inflammatory drug.

Supplemental Table A2 Results of subgroup analyses of mortality risk among diabetic patients with HBV infection and matched control subjects

Characteristic	Adjusted[a]		Interaction p value
	Hazard ratio (95% CI)	p value	
Sex			
Male	0.785 (0.754–0.817)	<0.001	0.030
Female	0.714 (0.667–0.765)	<0.001	
Age			
20–65 years	0.749 (0.719–0.781)	<0.001	0.165
>65 years	0.770 (0.724–0.819)	<0.001	
Hypertension			
Yes	0.870 (0.831–0.912)	<0.001	<0.001
No	0.668 (0.635–0.703)	<0.001	
Coronary artery disease			
Yes	0.786 (0.735–0.840)	<0.001	0.345
No	0.759 (0.729–0.790)	<0.001	
Chronic kidney disease			
Yes	0.818 (0.757–0.886)	<0.001	0.114
No	0.754 (0.726–0.784)	<0.001	
Dyslipidaemia			
Yes	0.936 (0.887–0.986)	0.014	<0.001
No	0.630 (0.602–0.659)	<0.001	
Use of insulin			
Yes	0.932 (0.792–1.096)	0.395	0.020
No	0.759 (0.733–0.786)	<0.001	
Adapted Diabetes Complications Severity Index score			
0–1	0.749 (0.719–0.780)	<0.001	0.010
≥2	0.826 (0.774–0.881)	<0.001	

[a]Adjusted for monthly income, urbanisation level, Charlson Comorbidity Index score, dipeptidyl peptidase-4 inhibitor use, metformin use, sulfonylurea use, alpha blocker use, dyslipidaemia, atrial fibrillation, peripheral vascular disease, and heart failure.

Supplemental Table A3 Results of subgroup analysis of risk of MACE among diabetic patients with HBV infection and matched control subjects

Characteristic	Adjusted[a]		Interaction p value
	Hazard ratio (95% CI)	p value	
Sex			
Male	0.526 (0.480–0.576)	<0.001	0.002
Female	0.686 (0.596–0.789)	<0.001	
Age			
20–65 years	0.579 (0.528–0.636)	<0.001	0.799
>65 years	0.575 (0.502–0.659)	<0.001	
Hypertension			
Yes	0.619 (0.563–0.680)	<0.001	0.005
No	0.493 (0.431–0.564)	<0.001	
Coronary artery disease			
Yes	0.670 (0.585–0.766)	<0.001	0.005
No	0.533 (0.486–0.585)	<0.001	
Chronic kidney disease			
Yes	0.638 (0.536–0.760)	<0.001	0.158
No	0.558 (0.512–0.607)	<0.001	
Dyslipidaemia			
Yes	0.638 (0.576–0.707)	<0.001	0.003
No	0.501 (0.447–0.562)	<0.001	
Use of insulin			
Yes	1.143 (0.734–1.781)	0.555	0.005
No	0.560 (0.518–0.605)	<0.001	
Adapted Diabetes Complications Severity Index score			
0–1	0.545 (0.497–0.598)	<0.001	0.044
≥2	0.640 (0.557–0.735)	<0.001	

[a]Adjusted for monthly income, urbanisation level, Charlson Comorbidity Index score, dipeptidyl peptidase-4 inhibitor use, metformin use, sulfonylurea use, alpha blocker use, dyslipidaemia, atrial fibrillation, peripheral vascular disease, and heart failure.